Medical device startup **Telesair** secures **$22 million in Series A funding** to advance its hospital-grade respiratory products. The company, based in Irvine, is developing a device intended for home use alongside its existing offerings. Telesair targets scalable solutions for respiratory care in clinical and non-clinical settings.
Telesair secures $22 million in funding from Pasaca Capital and Honeywell to develop a **High Flow Oxygen** solution. The investment aims to support patient transitions into **homecare settings**, addressing gaps in respiratory care delivery. Telesair’s technology targets improved accessibility and efficiency for patients requiring oxygen therapy outside hospitals.
Telesair secures $22 million in Series A funding to advance its hospital-to-home respiratory care products. The company designs medical devices aimed at improving patient transitions from hospital settings to home environments. This funding supports further development of its digital health solutions for respiratory management.
Telesair secures $22 million in Series A funding to advance its respiratory care solutions. The Irvine, CA-based company focuses on developing technologies for respiratory health management. This funding round highlights growing investor interest in respiratory health innovation.
Telesair secures a **$22 million Series A round** led by Pasaca Capital, with participation from Honeywell and investors including ZhenCheng Capital, Shangbay Capital, and Device of Tomorrow Capital. The funding supports Telesair’s development of next-generation respiratory care solutions. Honeywell joins as a strategic backer, aligning with the company’s focus on advanced medical technologies.
Ultrastar Ventures
Sunnyvale-based Ultrastar Ventures: A venture capital firm.